Authors
Katharina Strempfl 1, Marco Zattoni 2, Heike Mrowetz 2, Michael S Unger 2, Nikolaos Schörghofer 2, Barbara Altendorfer 2, Jörg Neddens 3, Stefanie Flunkert 3, Birgit Hutter-Paier 4, Yachao He 5, Johan Wallin 5, Rodolphe W Poupardin 6, Frank Pietrantonio 7, Nadine Paiement 7, Horst Zerbe 7, Thomas Felder 8, Per Svenningsson 5, Ludwig Aigner 9
Affiliations
1Institute of Molecular Regenerative Medicine, Paracelsus Medical University, Salzburg, Austria; Scantox Neuro GmbH, Grambach, Austria.
2Institute of Molecular Regenerative Medicine, Paracelsus Medical University, Salzburg, Austria.
3Scantox Neuro GmbH, Grambach, Austria.
4QPS Austria GmbH, Neuropharmacology, Grambach, Austria.
5Department of Clinical Neuroscience, Neuro Svenningsson, J5:20 Bioclinicum, Karolinska, Universitetssjukhuset, Stockholm, Sweden.
6Institute of Experimental and Clinical Cell Therapy, Paracelsus Medical University, Salzburg, Austria.
7IntelGenx Corp., Saint-Laurent, QC H4S 1Y2, Canada.
8Department of Laboratory Medicine, Paracelsus Medical University, 5020 Salzburg, Austria.
9Institute of Molecular Regenerative Medicine, Paracelsus Medical University, Salzburg, Austria; Austrian Cluster for Tissue Regeneration, Austria.
General info
- Year: 2025
- Division: Discovery
- Disease: Parkinson's disease
- Model: Line 61 mice
- Material: Publication
- DOI: 10.1016/j.neurot.2025.e00690
- Keywords: Drug treatment, Repurposing, Activated microglia, Alpha-synuclein, Transcriptomics, Histology, Biochemistry, Beam walk test, Striatum, Cerebellum, SGK1, NFkappaB
